ALX Oncology Holdings, Inc. (ALXO)
| Market Cap | 3.02B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.99M |
| Shares Out | 40.34M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,632 |
| Open | 77.85 |
| Previous Close | 78.78 |
| Day's Range | 74.96 - 79.00 |
| 52-Week Range | 32.51 - 117.45 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 97.29 (+29.8%) |
| Est. Earnings Date | Nov 11, 2021 |
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price forecast is 97.29, which is an increase of 29.75% from the latest price.
News
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent an...
-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
The 3 Best Biotech Stocks to Buy Right Now
Let your portfolio reflect your personality.
So What's Going On With ALX Oncology's Stock?
ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday. ALX Oncology is...
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkp...
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pemb...
The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated
ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know
ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bigg...
ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer
ALX Oncology Holdings Inc (NASDAQ: ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastroesop...
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Pat...
-- ORR of 72% Observed in Patients with > 2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on July 6 th at 8:30 ...
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
--Interim report completed by ALX for a standard ongoing non-clinical safety study
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in...
Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASP...
ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpo...
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pemb...
- The first of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated
Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark
Alx Oncology Holding sees its Relative Strength Rating enter the 80-plus level. The post Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer ...
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 chec...
Top Wall Street analysts bet on these stocks for long-term growth
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operat...
BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
Why Earnings Season Could Be Great for ALX Oncology (ALXO)
ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021
BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
ALX Oncology: Targeting The CD47 Receptor For Cancers
ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.
ALX Oncology: All Their Eggs In The Proverbial Basket
ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only having a single...